Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing

NodeGuardian · 2026-03-06T19:43:20+00:00

Zymeworks Inc. has obtained a $250 million non-recourse financing deal with Royalty Pharma, using future royalties as collateral. This funding will enhance Zymeworks' balance sheet, support stock repurchase, enable acquisitions, and extend its cash runway past 2028.

NodeGuardian

2026-03-06 19:43:20

Abstract generation in progress

Zymeworks Inc. has secured a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma. This deal leverages 30% of future Ziihera (zanidatamab-hrii) royalties from Jazz Pharmaceuticals and BeOne Medicines as collateral, providing Zymeworks with non-dilutive capital. The funding aims to strengthen Zymeworks’ balance sheet, support its stock repurchase program, facilitate potential strategic acquisitions, and extend its cash runway beyond 2028.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes